Triphenylamine zwitterionic compounds and preparation methods and applications thereof

By developing a new structure of tripaniline zwitterionic compound, the problem of resistance to existing antibacterial agents was solved, and effective inhibition of Staphylococcus aureus, E. coli and Pseudomonas aeruginosa was achieved, showing its Application potential in the field of antibacterial technology.

CN118439996BActive Publication Date: 2024-11-12GUANGDONG INST OF MICROBIOLOGY GUANGDONG DETECTION CENT OF MICROBIOLOGY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410562928.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-05-08
Publication Date
2024-11-12
Estimated Expiration
2044-05-08

AI Technical Summary

Technical Problem

After long-term use of existing antibacterial agents, microorganisms are prone to resistance to traditional bactericidal drugs, and lack of new structures of antibacterial agents.

Method used

A structurally novel trianiline zwitterionic compound was developed, prepared by specific synthetic methods, for the preparation of antibacterial reagents against Staphylococcus aureus, E. coli and Pseudomonas aeruginosa. The structural formula of this compound is: R is selected from four different groups, synthesized by specific reaction steps and conditions, and has high antibacterial activity.

Benefits of technology

The synthesized tripaniline zwitterionic compounds show good antibacterial activity, have good antibacterial effects on Staphylococcus aureus, E. coli, and Pseudomonas aeruginosa, and are easy to synthesize, and have great application value.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FDA0005072949930000011
    Figure FDA0005072949930000011
  • Figure FDA0005072949930000012
    Figure FDA0005072949930000012
  • Figure FDA0005072949930000021
    Figure FDA0005072949930000021
Patent Text Reader

Abstract

The present invention discloses a triphenylamine zwitterionic compound and a preparation method and application thereof. The structural formula of the triphenylamine zwitterionic compound is shown in formula (III), and the preparation method thereof is as follows: 4-methylquinoline or 4-methylpyridine and 1,3-propane sultone are used as raw materials, and the first step product (I) or (II) is obtained by reaction, and the first step product (I) or (II) is reacted with diphenylamino-4-benzaldehyde (a) or 5-(4-(diphenylamino)phenyl)thiophene-2-carboxaldehyde (b) or 4'-(diphenylamino)-[1,1'-biphenyl]-4-carboxaldehyde (c) as raw materials to obtain a product triphenylamine zwitterionic compound (III). The triphenylamine zwitterionic compound exhibits antibacterial activity, especially has good antibacterial activity against Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, and can be used as an antibacterial agent.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of antibacterial, and in particular relates to a triphenylamine zwitterionic compound and a preparation method and application thereof. Background Art

[0002] Bacterial infection is a common disease and a common source of material or product deterioration in industry. It poses a serious threat to human health and industrial production. Although there are several types of bactericides or agents available in medicine and industry, with the long history of use of these agents, the self-survival ability of microorganisms has led to a certain degree of drug resistance. Discovering new antibacterial / bactericidal agents has become an important research topic in this field. High-throughput screening is one of the methods to obtain new antibacterial / bactericidal agents. The triphenylamine zwitterionic compounds obtained by screening may become new antibacterial / bactericidal agents. Summary of the invention

[0003] In view of the problems existing in the prior art, the present invention provides a triphenylamine zwitterionic compound with novel structure and good antibacterial activity against Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.

[0004] The first object of the present invention is to provide a triphenylamine zwitterionic compound, wherein the structural formula of the triphenylamine zwitterionic compound is as shown in formula (III):

[0005]

[0006] The R is selected from

[0007] The second object of the present invention is to provide a method for preparing the above-mentioned triphenylamine zwitterionic compound, which comprises the following steps: using 4-methylquinoline or 4-methylpyridine and 1,3-propane sultone as raw materials, reacting to obtain the first-step product (I) or (II), and the first-step product (I) or (II) and diphenylamino-4-benzaldehyde (a) or 5-(4-(diphenylamino)phenyl)thiophene-2-carboxaldehyde (b) or 4'-(diphenylamino)-[1,1'-biphenyl]-4-carboxaldehyde (c) as raw materials to obtain the product triphenylamine zwitterionic compound (III). The synthesis reaction formula of the triphenylamine zwitterionic compound is:

[0008]

[0009] Preferably, the method comprises the following steps: a first step: adding 4-methylquinoline or 4-methylpyridine, 1,3-propane sultone and toluene into a reactor, heating and stirring to react, and obtaining the first step product (I) or (II); a second step: adding the first step product (I) or (II), diphenylamino-4-benzaldehyde (a) or 5-(4-(diphenylamino)phenyl)thiophene-2-carboxaldehyde (b) or 4'-(diphenylamino)-[1,1'-biphenyl]-4-carboxaldehyde (c), morpholine and methanol into a reactor, heating and stirring to react, and obtaining a triphenylamine zwitterionic compound.

[0010] Preferably, the molar ratio of 4-methylquinoline or 4-methylpyridine to 1,3-propane sultone in the first step is 1:1, and the heating and stirring reaction is a stirring reaction at 100°C.

[0011] Preferably, the ratio of the amount of the first step product (I) or (II), diphenylamino-4-benzaldehyde (a) or 5-(4-(diphenylamino)phenyl)thiophene-2-carboxaldehyde (b) or 4'-(diphenylamino)-[1,1'-biphenyl]-4-carboxaldehyde (c), and morpholine in the second step is 1:1:1.1; and the heating and stirring reaction is a stirring reaction at 60°C.

[0012] The total yield of the preparation method of the present invention can be between 18% and 67%.

[0013] The third object of the present invention is to provide the use of the above-mentioned triphenylamine zwitterionic compound in the preparation of antibacterial agents.

[0014] Preferably, the antibacterial agent is an agent against Staphylococcus aureus, Escherichia coli and / or Pseudomonas aeruginosa.

[0015] A fourth object of the present invention is to provide an antibacterial agent comprising the above-mentioned triphenylamine-based zwitterionic compound as an active ingredient.

[0016] Preferably, the antibacterial agent is an agent against Staphylococcus aureus, Escherichia coli and / or Pseudomonas aeruginosa.

[0017] Preferably, the concentration of the triphenylamine zwitterionic compound is 4-8 μg / mL.

[0018] Compared with the prior art, the present invention has the following beneficial effects:

[0019] The triphenylamine zwitterionic compound synthesized by the invention is easy to synthesize and exhibits good antibacterial activity, and has good antibacterial activity against Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. As a triphenylamine zwitterionic compound with a completely new structure, it has great application value in the field of antibacterial technology. DETAILED DESCRIPTION

[0020] The synthesis reaction formulas of the triphenylamine zwitterionic compounds IIIa, IIIb, IIIc, IIId, IIIe and IIIf of the present invention are as follows:

[0021]

[0022] The following examples are provided to further illustrate the present invention, rather than to limit the present invention.

[0023] Embodiment 1:

[0024] Preparation steps of (E)-3-(4-(4-(diphenylamino)phenylvinyl)quinolin-1-ium-1-yl)propane-1-sulfonate (IIIa):

[0025]

[0026] 50 mmol of 4-methylquinoline, 50 mmol of 1,3-propane sultone and 40 mL of toluene were added to a 100 mL flask, and stirred at 100° C. for 10 hours. After the reaction was completed, the mixture was cooled, filtered, and the residue was washed with 8 mL of ethanol. The residue was recrystallized from ethanol to obtain product (I) with a yield of 95%.

[0027] 1 mmol of the first step product (I), 1 mmol of diphenylamino-4-benzaldehyde, 0.1 mL of morpholine and 20 mL of methanol were added to a sealed reaction vessel, and the reaction was stirred at 60° C. for 1.5 hours. After the reaction was completed, the product was dried under reduced pressure and purified by silica gel column chromatography (200-300 mesh, eluent was methanol: dichloromethane, gradient elution: dichloromethane for 10 min, 0-20% methanol by volume for 20 min, 20% methanol by volume for 10 min, 20-100% methanol by volume for 20 min, methanol for 10 min), and the product emitting purple-red light under 365 nm light irradiation in the 20% methanol for 10 min section was collected. After reduced pressure and dried, the purple target product (IIIa) was obtained, with an Rf value of 0.80 (volume ratio of methanol: dichloromethane=1:6), and a yield of 40%. 1HNMR(600MHz,DMSO-d6,δ):9.29(d,1H,quinoline),9.01(d,1H,quinoline),8.63(d,1H,quin oline),8.45(d,1H,quinoline),8.23(t,1H,quinoline),8.15(s,2H,vinyl),8.00(t,1H,quin oline),7.89(d,2H,benzene),7.41(t,4H,benzene),7.16(m,6H,benzene),6.98(d,2H,benzene),5.10(t,2H,methylene),2.57(t,2H,methylene),2.27(m,2H,methylene).HRMS(ESI):m / z calcd forC 32 H 29 N2O3S + :521.1893[M+H] + ;found:521.1898.m / z calcd for C 32 H 28 N2O3SNa + :543.1712[M+Na] + ;found:543.1721.

[0028] Embodiment 2:

[0029] Preparation steps of (E)-3-(4-(2-(5-(4-(diphenylamino)phenyl)thiophen-2-yl)vinyl)quinolin-1-ium-1-yl)propane-1-sulfonate (IIIb):

[0030]

[0031] 50 mmol of 4-methylquinoline, 50 mmol of 1,3-propane sultone and 40 mL of toluene were added to a 100 mL flask, and stirred at 100° C. for 10 hours. After the reaction was completed, the mixture was cooled, filtered, and the residue was washed with 8 mL of ethanol. The residue was recrystallized from ethanol to obtain product (I) with a yield of 95%.

[0032] 1 mmol of the first step product (I), 1 mmol of 5-(4-(diphenylamino)phenyl)thiophene-2-carboxaldehyde, 0.1 mL of morpholine and 100 mL of methanol were added to a sealed reaction kettle, and the mixture was stirred at 60° C. for 6 hours. After the reaction was completed, the mixture was dried under reduced pressure and purified by silica gel column chromatography (200-300 mesh, eluent was methanol:dichloromethane, gradient elution: dichloromethane for 10 min, 0-20% methanol by volume for 20 min, 20% methanol by volume for 10 min, 20-100% methanol by volume for 20 min, methanol for 10 min), and the product under 20% methanol for 10 min was collected and dried under reduced pressure to obtain the target product (IIIb) with an Rf value of 0.6 (volume ratio of methanol:dichloromethane=1:6) and a yield of 70%. 1 H NMR(600MHz,DMSO-d6,δ):9.30(d,1H,quinoline),8.95(d,1H,quinoline),8.63(d,1H,quinoline),8.43(d,1H ,quinoline),8.40(d,1H,vinyl),8.24(t,1H,quinoline),8.01(t,1H,quinoline),7.96(d,1H,vinyl),7.76(d ,1H,thiophene),7.68(d,2H,benzene),7.59(d,1H,thiophene),7.37(t,4H,benzene),7.11(m,6H,benzene),7 .01(d,2H,benzene),5.10(t,2H,methylene),2.57(t,2H,methylene),2.27(m,2H,methylene).HRMS(ESI):m / z calcd for C 38 H 33 N2O3S + :597.2206[M+H] + ;found:597.2212.HRMS(ESI):m / z calcd for C 36 H 31 N2O3S2 + :603.1770[M+H] + ;found:603.1777.m / zcalcd for C 36 H 30 N2O3S2Na + :625.1590[M+Na] + ;found:625.1595.

[0033] Embodiment 3:

[0034] Preparation steps of (E)-3-(4-(2-(4'-(diphenylamino)-[1,1'-biphenyl]-4-yl)vinyl)quinolin-1-ium-1-yl)propane-1-sulfonate (IIIc):

[0035]

[0036] 50 mmol of 4-methylquinoline, 50 mmol of 1,3-propane sultone and 40 mL of toluene were added to a 100 mL flask, and stirred at 100° C. for 10 hours. After the reaction was completed, the mixture was cooled, filtered, and the residue was washed with 8 mL of ethanol. The residue was recrystallized from ethanol to obtain product (I) with a yield of 95%.

[0037] 1 mmol of the first step product (I), 1 mmol of 4'-(diphenylamino)-[1,1'-biphenyl]-4-carboxaldehyde, 0.1 mL of morpholine and 120 mL of methanol were added to a sealed reaction vessel, stirred and reacted at 60°C for 24 hours. After the reaction was completed, the mixture was evaporated under reduced pressure and purified by silica gel column chromatography (200-300 mesh, eluent was methanol:dichloromethane, gradient elution: dichloromethane for 5 min, 0-20% methanol by volume for 20 min, 20% methanol by volume for 10 min, 20-100% methanol by volume for 20 min, methanol for 10 min), and the product emitting orange light under 365 nm light irradiation in the 20% methanol for 10 min period was collected. The target product (IIIc) was evaporated under reduced pressure and evaporated, with an Rf value of 0.77 (volume ratio of methanol:dichloromethane = 1:6) and a yield of 34%. 1 HNMR(600MHz,DMSO-d6,δ):9.39(d,1H,quinoline),9.10(d,1H,quinoline),8.68(d,1H,quinoline),8.53 (d,1H,quinoline),8.40(d,1H,vinyl),8.27(t,1H,quinoline),8.22(d,1H,vinyl),8.08(m,3H,quinoline andbenzene),7.84(d,2H,benzene),7.74(d,2H,benzene),7.36(t,4H,benzene),7.10(m,8H,benzene),5.14(t,2H,methylene),2.58(t,2H,methylene),2.29(m,2H,methylene).HRMS(ESI):m / z calcd for C 38 H 33 N2O3S +:597.2206[M+H] + ;found:597.2212.

[0038] Embodiment 4:

[0039] Preparation steps of (E)-3-(4-(4-(diphenylamino)phenylvinyl)pyridin-1-ium-1-yl)propane-1-sulfonate (IIId):

[0040]

[0041] 50 mmol of 4-methylpyridine, 50 mmol of 1,3-propane sultone and 40 mL of toluene were added into a 100 mL flask, stirred and reacted at 100 °C for 6 hours. After the reaction was completed, the mixture was cooled and allowed to stand. The upper layer of toluene was removed, 12 mL of ethanol was added for dispersion, and the mixture was filtered with suction. The residue was rinsed with 8 mL of ethanol and air-dried to obtain product (II) with a yield of 60%.

[0042] 1 mmol of the first step product (II), 1 mmol of diphenylamino-4-benzaldehyde, 0.1 mL of morpholine and 20 mL of methanol were added to a sealed reactor and stirred at 60° C. for 2 hours. After the reaction was completed, the mixture was cooled, filtered and the residue was air-dried to obtain the target product (IIId) with an Rf value of 0.34 (volume ratio of methanol: dichloromethane = 1:6) and a yield of 43%. 1 H NMR(600MHz,DMSO-d6,δ):8.88(d,2H,pyridine),8.16(d,2H,pyridine),7.96(d,1H,vinyl),7.63(d,2H,benzene),7.39(t,4H,benzene),7.32(d,1H,vinyl) ,7.18(t,2H,benzene),7.13(d,4H,benzene),6.96(d,2H,benzene),4.60(t,2H,methylene),2.42(t,2H,methylene),2.21(m,2H,methylene).HRMS(ESI):m / z calcd for C 28 H 26 N2O3SNa + :493.1556[M+Na] + ;found:493.1569.

[0043] Embodiment 5:

[0044] Preparation steps of (E)-3-(4-(2-(5-(4-(diphenylamino)phenyl)thiophen-2-yl)vinyl)pyridin-1-ium-1-yl)propane-1-sulfonate (IIIe):

[0045]

[0046] 50 mmol of 4-methylpyridine, 50 mmol of 1,3-propane sultone and 40 mL of toluene were added into a 100 mL flask, stirred and reacted at 100 °C for 6 hours. After the reaction was completed, the mixture was cooled and allowed to stand. The upper layer of toluene was removed, 12 mL of ethanol was added for dispersion, and the mixture was filtered with suction. The residue was rinsed with 8 mL of ethanol and air-dried to obtain product (II) with a yield of 60%.

[0047] 1 mmol of the first step product (II), 1 mmol of 5-(4-(diphenylamino)phenyl)thiophene-2-carbaldehyde, 0.1 mL of morpholine and 60 mL of methanol were added to a sealed reactor and stirred at 60° C. for 6 hours. After the reaction was completed, the mixture was cooled, filtered and the residue was air-dried to obtain the target product (IIIe) with an Rf value of 0.34 (volume ratio of methanol:dichloromethane=1:6) and a yield of 54%. 1 HNMR(600MHz,DMSO-d6,δ):8.89(d,2H,pyridine),8.21(d,1H,vinyl),8.17(d,2H,pyridine ),7.64(d,2H,benzene),7.51(d,2H,thiophene),7.36(t,4H,benzene),7.10(m,7H,benzene and vinyl),6.99(d,2H,benzene),4.60(t,2H,methylene),2.42(t,2H,methylene),2.21(m,2H,methylene).HRMS(ESI):m / z calcd for C 38 H 33 N2O3S + :597.2206[M+H] + ;found:597.2212.HRMS(ESI):m / z calcd for C 32 H 29 N2O3S2 + :553.1614[M+H] + ;found:553.1621.m / z calcd for C 32 H 28 N2O3S2Na + :575.1433[M+Na]+ ;found:575.1437.

[0048] Embodiment 6:

[0049] Preparation steps of (E)-3-(4-(2-(4'-(diphenylamino)-[1,1'-biphenyl]-4-yl)vinyl)pyridin-1-ium-1-yl)propane-1-sulfonate (IIIf):

[0050]

[0051] 50 mmol of 4-methylpyridine, 50 mmol of 1,3-propane sultone and 40 mL of toluene were added into a 100 mL flask, stirred and reacted at 100 °C for 6 hours. After the reaction was completed, the mixture was cooled and allowed to stand. The upper layer of toluene was removed, 12 mL of ethanol was added for dispersion, and the mixture was filtered with suction. The residue was rinsed with 8 mL of ethanol and air-dried to obtain product (II) with a yield of 60%.

[0052] 1 mmol of the first step product (II), 1 mmol of 4'-(diphenylamino)-[1,1'-biphenyl]-4-carboxaldehyde, 0.1 mL of morpholine and 60 mL of methanol were added to a sealed reaction kettle, stirred and reacted at 60°C for 24 hours. After the reaction was completed, the mixture was evaporated under reduced pressure and purified by silica gel column chromatography (200-300 mesh, eluent was methanol: dichloromethane, gradient elution: dichloromethane for 5 min, 0-20% methanol by volume for 20 min, 20% methanol by volume for 10 min, 20-100% methanol by volume for 20 min, methanol for 10 min), and the product emitting orange-red light under 365 nm light irradiation in the 20% methanol for 10 min period was collected. After reduced pressure and evaporated, the orange target product (IIIf) was obtained, with an Rf value of 0.54 (volume ratio of methanol: dichloromethane = 1:6) and a yield of 30%. 1 HNMR(600MHz,DMSO-d6,δ):8.88(d,2H,pyridine),8.16(d,2H,pyridine),8.08(d,2H,ben zene),7.96(d,1H,vinyl),7.84(d,2H,benzene),7.63(d,2H,benzene),7.39(t,4H,benzen e),7.32(d,1H,vinyl),7.18(t,2H,benzene),7.13(d,4H,benzene),6.96(d,2H,benzene),4.60(t,2H,methylene),2.42(t,2H,methylene),2.21(m,2H,methylene).HRMS(ESI):m / z calcd forC 34 H31 N2O3S + :547.2049[M+H] + ;found:547.2052.

[0053] Embodiment 7:

[0054] Antimicrobial activity test of target compounds:

[0055] The antibacterial activity of the target compound (triphenylamine zwitterionic compound prepared in Example 1-6) against Staphylococcus aureus (Staphylococcus aureus ATCC 6538P), Escherichia coli (Escherichia coli ATCC 8739), and Pseudomonas aeruginosa (Pseudomonas aeruginosa ATCC 9027) was determined by using 2-methyl-4-isothiazolin-3-one (MIT) as a positive control agent and the MIC of the target compound was determined by the microdilution method.

[0056] The experimental steps of microdilution method are as follows:

[0057] Add 200 μL of a 256 μg / mL aqueous solution of the sample to be tested (2-methyl-4-isothiazoline-3-one and the triphenylamine zwitterionic compound prepared in Examples 1-6) to the first column of the 96-well plate, add 100 μL of MH broth to columns 2-12 respectively, then take 100 μL from column 1 and add it to column 2 to mix, then take 100 μL from column 2 and add it to column 3 to mix, and so on, finally take 100 μL from column 10 and add it to column 11 to mix, then take out 100 μL of excess liquid and discard. Take 100 μL of 10 6 cfu / mL of bacterial solution was added to each well in columns 1-11, and 100 μL of the concentration of 10 6 cfu / mL of bacterial solution was added to the first four wells of the 12th column, and 100μL of MH broth was added to the last four wells of the 12th column. The final volume of each well was 200μL. The concentrations of the samples to be tested in columns 1-11 were 128, 64, 32, 16, 8, 4, 2, 1, 0.5, 0.25, and 0.125μg / mL, respectively. The first four wells of the 12th column were bacteria-free (bacterial growth control), and the last four wells of the 12th column were bacteria-free (sterile blank control). Three replicates were made for each sample to be tested. After the 96-well plate was incubated in a 37°C oven for 24 hours, the OD was measured using an enzyme reader. 600 Value, OD 600 The concentration of the wells with values ​​close to the sterile blank control is the minimum inhibitory concentration (MIC).

[0058] The results show:

[0059] (1) The MICs of (E)-3-(4-(4-(diphenylamino)phenylvinyl)quinolin-1-ium-1-yl)propane-1-sulfonate (IIIa) against Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa were 2 μg / mL, 2 μg / mL, and 4 μg / mL, respectively.

[0060] (2) The MICs of (E)-3-(4-(2-(5-(4-(diphenylamino)phenyl)thiophen-2-yl)vinyl)quinolin-1-ium-1-yl)propane-1-sulfonate (IIIb) against Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa were 4 μg / mL, 4 μg / mL, and 4 μg / mL, respectively.

[0061] (3) The MICs of (E)-3-(4-(2-(4'-(diphenylamino)-[1,1'-biphenyl]-4-yl)vinyl)quinolin-1-ium-1-yl)propane-1-sulfonate (IIIc) against Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa were 2 μg / mL, 2 μg / mL, and 4 μg / mL, respectively.

[0062] (4) The MICs of (E)-3-(4-(4-(diphenylamino)phenylvinyl)pyridin-1-ium-1-yl)propane-1-sulfonate (IIId) against Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa were 2 μg / mL, 4 μg / mL, and 4 μg / mL, respectively.

[0063] (5) The MICs of (E)-3-(4-(2-(5-(4-(diphenylamino)phenyl)thiophen-2-yl)vinyl)pyridin-1-ium-1-yl)propane-1-sulfonate (IIIe) against Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa were 4 μg / mL, 4 μg / mL, and 8 μg / mL, respectively.

[0064] (6) The MICs of (E)-3-(4-(2-(4'-(diphenylamino)-[1,1'-biphenyl]-4-yl)vinyl)pyridin-1-ium-1-yl)propane-1-sulfonate (IIIf) against Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa were 4 μg / mL, 4 μg / mL, and 8 μg / mL, respectively.

[0065] The above are only preferred embodiments of the present invention. It should be noted that the above preferred embodiments should not be regarded as limiting the present invention, and the protection scope of the present invention should be based on the scope defined by the claims. For ordinary technicians in this technical field, several improvements and modifications can be made without departing from the spirit and scope of the present invention, and these improvements and modifications should also be regarded as the protection scope of the present invention.

Claims

1. A triphenylamine zwitterionic compound, wherein the structural formula of the triphenylamine zwitterionic compound is shown in formula (III): The R is selected from 2. A method for preparing the triphenylamine zwitterionic compound according to claim 1, characterized in that: The method comprises the following steps: using 4-methylquinoline or 4-methylpyridine and 1,3-propane sultone as raw materials to react to obtain a first-step product (I) or (II); using the first-step product (I) or (II) and diphenylamino-4-benzaldehyde (a) or 5-(4-(diphenylamino)phenyl)thiophene-2-carboxaldehyde (b) or 4'-(diphenylamino)-[1,1'-biphenyl]-4-carboxaldehyde (c) as raw materials to obtain a product triphenylamine zwitterionic compound (III); the synthesis reaction formula of the triphenylamine zwitterionic compound is:

3. The preparation method according to claim 2, characterized in that: The following steps are involved: The first step is to add 4-methylquinoline or 4-methylpyridine, 1,3-propane sultone and toluene into a reactor, and heat and stir to react, so as to obtain the first-step product (I) or (II); the second step is to add the first-step product (I) or (II), diphenylamino-4-benzaldehyde (a) or 5-(4-(diphenylamino)phenyl)thiophene-2-carboxaldehyde (b) or 4'-(diphenylamino)-[1,1'-biphenyl]-4-carboxaldehyde (c), morpholine and methanol into a reactor, and heat and stir to react, so as to obtain a triphenylamine zwitterionic compound.

4. The preparation method according to claim 3, characterized in that: The ratio of the amount of 4-methylquinoline or 4-methylpyridine to 1,3-propane sultone in the first step is 1:1, and the heating and stirring reaction is a stirring reaction at 100°C.

5. The preparation method according to claim 3, characterized in that: In the second step, the ratio of the amount of the first step product (I) or (II), diphenylamino-4-benzaldehyde (a) or 5-(4-(diphenylamino)phenyl)thiophene-2-carboxaldehyde (b) or 4'-(diphenylamino)-[1,1'-biphenyl]-4-carboxaldehyde (c), and morpholine is 1:1:1.1; and the heating and stirring reaction is a stirring reaction at 60°C.

6. Use of the triphenylamine zwitterionic compound according to claim 1 in the preparation of antibacterial agents.

7. The use according to claim 6, characterized in that: The antibacterial agent is an agent against Staphylococcus aureus, Escherichia coli and / or Pseudomonas aeruginosa.

8. An antibacterial agent, characterized in that The invention contains the triphenylamine zwitterionic compound according to claim 1 as an active ingredient.

9. The antibacterial agent according to claim 8, characterized in that The antibacterial agent is an agent against Staphylococcus aureus, Escherichia coli and / or Pseudomonas aeruginosa.

10. The antibacterial agent according to claim 8, characterized in that The concentration of the triphenylamine zwitterionic compound is 4-8 μg / mL.